1887
Volume 2006, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Thyroid associated opthalmopathy (TAO) may precede, coincide, or follow the systemic complications of dysthyroidism it can present gradually as dry eyes, puffy eyelids, ocular pressure or pain, field loss, diplopia with 3rd, 4th, 6th nerve palsies we report a 22 year old Filipina female who presented with sudden onset of diplopia, pain, headache, with no sign or symptom of dysthyroidism and clinically sounds to have 3rd, 4th, and 6th, nerve palsies (left eye) the case represents diagnostic dilemma that's why found it worth to be reported

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2006.2.22
2006-11-01
2020-09-23
Loading full text...

Full text loading...

References

  1. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14::747.
    [Google Scholar]
  2. Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid. 1992; 2::229.
    [Google Scholar]
  3. Dickinson AJ, Vaidya B, Miller M, et al., Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. J Clin Endocrinal Metab. 2004; 89::5910.
    [Google Scholar]
  4. Wemeau JL, Caron P, Beckers A, et al., Octreotide (longacting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2005; 90::841.
    [Google Scholar]
  5. Tallstedt L, Lundell G, Torring O, et al., Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992; 326::1733.
    [Google Scholar]
  6. Dickinson AJ, Vaidya B, Miller M, et al., Double Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab. 2004; 89::5910.
    [Google Scholar]
  7. Eastell R, Devogelaer JP, Peel NF, et al., Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000; 11::331.
    [Google Scholar]
  8. Prummel MF, Wiersinga WM. Medical management of Graves'ophthalmopathy. Thyroid. 1995; 5::231.
    [Google Scholar]
  9. Prummel MF, Mourits MP, Blank L, et al., Randomized double blind controlled of prednisolone versus radiotherapy in Graves'ophthalmopathy. Lancet. 1993; 342::949.
    [Google Scholar]
  10. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al., Radiotherapy for Graves' orbitopathy: randomized placebo-controlled study. Lancet. 2000; 355::1505.
    [Google Scholar]
  11. Gorman CA, Garrity JA, Fatourechi V, et al., A prospective, randomized, double blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001; 108::1523.
    [Google Scholar]
  12. Bartalena L, Marcocci C, Chiovato L, et al., Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983; 56::1139.
    [Google Scholar]
  13. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology. 1994; 101::223.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2006.2.22
Loading
  • Article Type: Case Report
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error